StockNews.com cut shares of Dr. Reddy’s Laboratories (NYSE:RDY – Free Report) from a strong-buy rating to a buy rating in a research report report published on Thursday morning. Separately, Barclays lifted their price target on shares of Dr. Reddy’s Laboratories from $80.00 to $81.00 and gave the company an overweight rating in a research note […]